



EUROSTARS

The Eurostars Programme is a European Joint Programme dedicated to R&D performing SMEs, co-funded by the European Communities and 33 EUREKA member countries. It aims to stimulate SMEs to lead international collaborative research and innovation projects by easing access to support and funding. It is fine-tuned to focus on the needs of SMEs, and specifically targets the development of new products, processes and services and the access to transnational and international markets.

The main participant of any Eurostars consortium must be an R&D SME in order to satisfy the Eurostars eligibility criteria. Usually consortia are set up with R&D SMEs, SMEs, Research Institutes and Universities. An average project consortium is composed of 3-4 participants from 2-3 countries involved in the programme. Duration of the projects are roughly 29 months with a total budget of 1,4 M€. The bottom-up approach gives the freedom to participants to launch their projects in any technological and market area.

For more information about the EUROSTARS programme please visit: www.eurostars-eureka.eu

Please note that the programmes mentioned above are not the complete list of funding opportunities for Health research. There are further funding possibilities like ERA-NET calls, Eurotransbio etc...

A network of 27 partners from 22 countries is there to assist you free of charge.



Project coordinator: Ines Haberl, ines.haberl@ffg.at

Interested? Contact your national expert now!



Alternative Funding Opportunities for SMEs in Health Research

Fit for Health supports SMEs & researchers

in Health-oriented FP7 projects from the research idea to the exploitation of research results

www.fitforhealth.eu



Health Programme DG SANCO

The second programme of community action in the field of Health 2008-2013 is the main instrument, the European Commission uses to implement the EU Health Strategy. It came into force on 1 January 2008 and is intended to complement, support and add value to the policies of the Member States and contribute to increase solidarity and prosperity in the European Union by protecting and promoting human health and safety and by improving public health.

The Health Programme 2008-2013 is managed by the European Commission (EC) with the assistance of the Executive Agency for Health and Consumers (EAHC). The total budget for the programme is 321,5 M€ and it is implemented by means of annual work plans which set out priority areas and the criteria for funding actions under the Programme. Participation is open to a wide range of organisations, including research institutes and universities, public authorities, NGO's and commercial firms.

The programme has three overarching objectives. It seeks to:

- improve citizens' health security,
- promote health and reduce health inequalities, increasing healthy life years and promoting healthy ageing,
- generate and disseminate health information and knowledge, exchanging knowledge and best practice on health issues.

For more information about the Health Programme please visit: http://ec.europa.eu/health/programme/policy/index_en.htm

The European & Developing Countries Clinical Trials Partnership (EDCTP)

The European & Developing Countries Clinical Trials Partnership (EDCTP) is a partnership of 14 EU countries, Switzerland and Norway, and 47 sub-Saharan African countries, which aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria, with a focus on phase II and III clinical trials in sub-Saharan Africa through a long-term partnership. EDCTP offers multicenter grants to support clinical trials, as well as networking and capacity building activities, in order to create a sustainable environment for conducting high-quality medical research in sub-Saharan Africa. The main EDCTP grant schemes are Integrated Projects, Senior Fellowships, Ethics, Member States Initiated projects and Networks of Excellence.

The current EDCTP programme will end in May 2015. It is anticipated that there will be an EDCTP II programme under Horizon 2020, the EU Framework Programme for Research and Innovation (2014 to 2020).

For more information about EDCTP please visit: <http://www.edctp.org/Home.162.0.html>

The Innovative Medicines Initiative (IMI)



The Innovative Medicines Initiative (IMI) is Europe's largest public-private partnership aiming to improve the drug development process by supporting a more efficient discovery and development of better and safer medicines for patients. IMI is a Joint Undertaking between the European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA).

With a 2 billion € budget, IMI supports collaborative research projects and builds networks of industrial and academic experts in Europe that will boost innovation in healthcare. Every year, IMI launches a new Call for proposals. Through the Calls and the consecutive selection process, IMI aims to support research activities that will speed up

the discovery and development of safer and more effective medicines. The open and competitive Calls for project proposals focus on research topics in the areas of safety and efficacy, knowledge management and education and training. The research consortia participating in IMI projects consist of large biopharmaceutical companies that are members of EFPIA, and a variety of other partners, such as SMEs, patients' organisations, universities and other research organisations, hospitals, regulatory agencies or any other industrial partners.

For more information about IMI please visit: www.imi.europa.eu/content/mission